New Developments in Liposomal Drug Delivery. Chem. Rev. 2015, 115, 10938–10966. [CrossRef] 43. Ishida, T.; Harashima, H.; Kiwada, H. Liposome clearance. Biosci. Rep. 2002, 22, 197–224. [CrossRef] [PubMed] 44. Ringsdorf, H. Structure and properties of pharma...
New drug candidates for liposomal delivery identified by computer modeling of liposomes' remote loading and leakage. J. Control. Release 252, 18-27.Cern A, Marcus D, Tropsha A, Barenholz Y, Goldblum A. New drug candidates for liposomal delivery identified by computer modeling of liposomes' ...
Zylberberg C, Matosevic S (2016) Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. Drug delivery 23(9): 3319-3329.Zylberberg C, Matosevic S. Pharmaceutical liposomal drug delivery: a review of new delivery systems and a ...
andYevgeniya Plekhov, M.S.(Senior Scientist), may have overcome the limitations of previous treatments by creating a new formulation of pH-targeted liposomal doxorubicin. As tumors develop, they create a more acidic environment in malignant tissues. In contrast...
Current developments in nanotechnology for cancer treatment. Mater Today: Proc. 2022;48:1754–8. CAS Google Scholar Martin F, Melnik K, West T, Shapiro J, Cohen M, Boiarski A, Ferrari M. Acute toxicity of intravenously administered microfabricated silicon dioxide drug delivery particles in ...
In this context, some nanoplatforms have been designed to efficiently deliver molecular, cellular, or subcellular vaccines to BC cells, increasing the efficacy and persistence of anti-tumor immunity while minimizing undesirable side effects. Immunostimulatory nano-adjuvants, liposomal-based vaccines, ...
in vivo and accumulate in tumor sites via the enhanced permeability and retention (EPR) effect, thereby improving drug delivery efficiency [103]. However, inorganic nanomaterials pose significant toxicity concerns due to their difficulty in degradation and clearance from the body, potentially leading to...
A liposomal formula- tion of the tetraene nystatin has undergone extensive testing preclinically and in clinical trials25. However, the results of phase III clinical trials for treatment of fever in neutropenia and in cryptococcal meningitis have not been reported in detail or published in the peer...
Burke, The use of muramyl peptides as vaccine adjuvants, in: W.C. Koff, H.R. Six (Eds.), Vaccine Research and Developments, Marcel Dekker, New York, 1992, pp. 89–114. Google Scholar 13 R Edelman Vaccine adjuvants Rev. Infect. Dis., 2 (1980), pp. 370-383 CrossrefView in ...
In this section, we focus on liposomal nanocarriers for delivery of autophagy modulators and subsequent cancer therapy. The mTOR signaling pathway is an inhibitor of autophagy and consists of two complexes, including mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) [168]. mTOR induces ...